




**PATENT- OCH
REGISTRERINGSVERKET**

**Intyg
Certificate**



Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande *Pharmacia AB, Uppsala SE*
Applicant (s)

(21) Patentansökningsnummer *9402430-4*
Patent application number

(86) Ingivningsdatum *1994-07-11*
Date of filing

Stockholm, 1995-06-30

*För Patent- och registreringsverket
For the Patent- and Registration Office*

Åsa Dahlberg
Åsa Dahlberg

*Avgift
Fee*

PRIORITY DOCUMENT

**PATENT- OCH
REGISTRERINGSVERKET
SWEDEN**

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

KONJUGAT MELLAN MODIFIERAT SUPERANTIGEN OCH EN MÅLSÖKANDE FÖRENING SAMT ANVÄNDNING AV KONJUGATEN.

Superantigen är en grupp av föreningar, främst prot inner av viralt eller bakteriellt ursprung, som har förmåga att samti-
digt binda till MHC klass II antigen på mammalieceller och till V β -kedjan hos T-cell receptorn (TCR) med följd att T-lymfocyter aktiveras för lys av den MHC klass II bärande cellen. På grund av en moderat grad av polymorfi hos den bindande delen i V β -kedjan kommer en relativt stor andel T-lymfocyter att aktiv ras (jämfört med den aktivering som sker vid normal "antigen-processing") vid kontakt med ett superantigen.

Från början sattes begreppet superantigen främst i samband med olika stafylokockenterotoxiner (SEA, SEB, SEC₁, SEC₂, SED och SEE). När intresset val vackts upptäcktes ytterligare superantigen. Exempel är "toxic shock syndrome toxin 1" (TSST-1), "exfoliating toxins" (ExFt) som är associerade med "scalded skin syndrome", "Streptococcal pyrogenic exotoxin" A, B och C (SPE A, B och C), "mouse mammary tumor virus proteins" (MMTV), "Streptococcal M proteins", Clostridial perfringens enterotoxin (CPET) m.fl. För en översikt över superantigen och deras egenskaper, se Kotzin et al (Adv. Immunol. 54 (1993) 99-166).

Som funktionellt superantigen har man även betraktat Pseudomonas exotoxin A på grund resultat som indikerar detta toxin kan processas intracellulärt av "accessory cells" till fragment som sedan i sin tur kan uttryckas på cellytan för att där binda till V β -kedja med åtföljande aktivering av T-celler (Pseudomonas exotoxin A; Leegard et al., Cell. Immunol. 135 (1991) 372-382).

Superantigen som sådant har föreslagits som terapeutikum vid ett antal olika sjukdomar för att via allmän aktivering av immunsystemet uppnå kurativa effekter (Kalland et al., WO 9104053; Terman et al., WO 9110680; Terman et al., WO 9324136; Newell et al., Proc. Natl. Acad. Sci. USA 88 (1991) 1074-1078).

I samband med vaccin har man även föreslagit att använda superantigen som muterats till att sakna TCR bindand förmåga (Kappler & Marrak, WO 9314634).

Mutation av superantigen har tidigare beskrivits (Kappler & Marrak, WO 9314634; Kappler et al., J. Exp. Med. 175 (1992)

387-96; Grossman et al, J. Immunol. 147 (1991) 3274-81; Hufnagle et al., Infect. Immun 59 (1991) 2126-34).

Vi har tidigare för slaget att använda superantigen kovalent konjugerat med antikropp som terapeutikum för att lysera celler som uppvisar en struktur mot vilken antikroppen är riktad (Dohlsten et al., WO 9201470; Lando et al., Cancer Immunol. Immunother. 36 (1993) 223-8; Kalland et al., Med. Oncol. Tumor Pharmacother. 10 (1993) 37-47; Lando et al J. Immunol 150 (8 part 2) (1993) 114A (Joint Meeting of the American Association of Immunologists and the Clinical Immunology Society, Denver, Colorado, USA May 21-25 (1993)); Lando et al., Proc. Am. Assoc. Cancer Res. Annu. Meet. 33(0) (1992) 339 (Annual Meeting of the American Association for Cancer Research, San Diego, California USA, May 20-23 (1992)); and Dohlsten et al., Proc. Natl. Acad. Sci. USA 88 (1991) 9287-91). Aktuella sjukdomar har varit cancer, virusinfektioner, parasitangrepp, och autoimmuna sjukdomar och andra sjukdomar som är associerade med celler som uttrycker sjukdoms-specifika ytstrukturer. Det experimentella arbete som utförts har framst varit inriktat på konjugat innehållande rekombinantframställt SEA och olika anti-kancer antikroppar. Konjugaten som sådana har uppvisat något reducerad förmåga att binda till MHC klass II antigen jämfört med icke-konjugerad form av det superantigen som ingått i konjugaten. Huruvida en sånt förmåga att binda till MHC Klass II antigen är bra eller dåligt för att uppnå optimal lys och terapeutisk effekt har varit oklar.

Immunterapiförsök med SEA kemiskt konjugerat med tumörspecifik anti-idiotyp antikropp har tidigare beskrivits av Ochi et al (J. Immunol. 151 (1993) 3180-3186).

Uppfinningens mål

Ett första mål med uppfinningen är att förbättra tidigare kända superantigen-antikroppskonjugat med avseende på förhållandet mellan generell immunstimulering och riktad cytotox. Stimulering resulterar i aktiverade T-lymfocyter och är beroende av superantigenets förmåga att binda både till T-cell receptorn och MHC klass II antigen.

Ett andra mål med uppfinningen är att förbättra selektiviteten av lysen - mellan celler som exponerar antigenet (mot vil-

ket antikroppsdel av konjugatet är riktat) och andra celler som exponerar MHC klass II.

Ett tredje mål med uppfinningen är att erbjuda konjugat som kan användas som terapeutikum vid behandling av däggdjur som lider av cancer, autoimmuna sjukdomar, parasitangrepp, virusinfektion eller andra sjukdomar som är associerade med celler som på sin yta uttrycker strukturer som är specifika för respektive sjukdom.

Ett fjärde mål med uppfinningen är att generellt erbjuda konjugat av det aktuella slaget med sankt affinitet för MHC klass II antigen.

Uppfinningen

Uppfinningens huvudaspekt är ett konjugat som innehåller

- a) en biospecific affinitetsmotpart som är riktad mot en struktur till vilken man onskar binda konjugatet och
- b) en peptid som
 - i) är härledd från ett superantigen,
 - ii) har förmåga att binda till T-cell receptorns $V\beta$ -kedja, och
 - iii) har en modifierad förmåga att binda till MHC klass II antigen jämfört med det superantigen från vilket peptiden är härledd (vildtyp av superantigen = SA(wt)).

Peptiden och affinitetsmotparten är kovalent sammanbundna via en brygga (B).

Uppfinningens föredragna konjugat har förmåga att aktivera och styra T-lymfocyter till selektiv lys av celler som på sin yta uppvisar den struktur mot vilken affinitetsmotparten är riktad. Med detta avses att konjugaten skall förorsaka cytolys i en SADCC-metod (Superantigen Antibody Dependent mediated Cellular Cytotoxicity). Se den experimentella delen nedan och våra tidigare citerade publikationer som avser konjugat mellan superantigen och antikroppar (ex.viz Dohlsten et al., WO 9201470).

Strukturen hos uppfinningens konjugat är analog med tidigare beskrivna superantigen-antikropps-konjugat (Dohlsten et al., WO 9201470 som härmed inkorporeras "by reference"), d.v.s. konjugatet uppfyller formeln

T-B-SA(m)

dar T står för den biospecifika affinitetsmotpart n, SA(m) är det modifierade superantigenet (peptiden enligt ovan), och B är en kovalent brygga som sammanbinder T och SA(m).

5 T kan i princip vara vilken som helst struktur som binder via biospecifik affinitet till en motpart men är främst riktad mot en cellytestruktur, företrädesvis sjukdomsspecifika sådana enligt ovan. Den struktur mot vilken T är riktad är vanligtvis skild från (a) de V β -epitop, som den superantigenhärledda p p-tiden (SA(m)) binder till, och även (b) från den MHC klass II epitop, som det ursprungliga superantigenet binder till. T är främst valt bland interleukiner (ex.vis interleukin-2), hormoner, antikroppar eller antigenbindande fragment av en antikropp, tillväxtfaktorer, etc. Se t.ex. Woodworth, "Preclinical and Clinical Development of Cytokine Toxins" presenterat vid konferensen "Molecular Approaches to Cancer Immunotherapy", Asheville, North Carolina, november 7-11, 1993. För närvarande mindre viktiga exempel på T är polypeptider som binder till konstanta domäner i immunglobuliner (ex.vis proteinerna A, G och L), lektiner, streptavidin, biotin etc.

Vid prioritetsdagen ansågs det föredraget att T var en antikropp eller ett antigenbindande fragment av en antikropp (inkluderande Fab, F(ab)₂, Fv, "single chain" antikropp etc), speciellt antikroppsaktiva fragment (såsom Fab) av antikropp riktad mot den s.k. C242 epitopen (Lindholm et al., WO 9301303) eller andra kancerspecifika epitoper.

I det fall T är en antikropp är den främst monoklonal eller en blandning av ett ändligt antal monoklonaler (ex.vis 2, 3, 4, 5 eller flera). För icke-terapeutisk användning kan T svara mot en polyklonal antikropp.

T behöver nödvändigtvis inte ha polypeptidstruktur.

SA(m) är främst ett muterat superantigen men kan potentiellt även vara ett kemiskt modifierat superantigen, inkluderande fragment av superantigen med förmåga att binda till V β -kedjan i T-cell receptorn. Förmågan hos SA(m) att binda V β -kedja är företrädesvis riktad mot en struktur/epitop som är associerad med superantigenaktivering av T-celler.

Med muterat superantigen avses att dess ursprungliga förmåga att binda till MHC klass II antigen har modifierats på genetisk

nivå så att en eller flera aminosyror ersättes av andra, införas eller avlägsnas i det nativa superantigen t.

SA(m) kan vara uppbyggt av ett antal olika aminosyradel-
sekvenser, var och en härstammande från olika superantigen.

SA(m) som sådan kan uppvisa sänkt immunogenicitet och
toxicitet jämför med det ursprungliga superantigenet.

Potentiellt kommer andra grupper/substanser som har förmåga
att korsreagera med T-cell receptorns V β -kedja att kunna ut-
nyttjas ekvivalent med superantigen (SA(m)) som muterats enligt
ovan. Sådana grupper/substanser kan vara av icke-polypep-
tidstruktur.

Såväl T som SA(m) kan vara framställda med rekombinant tek-
nik.

Bryggan B kan väljas på samma sätt som tidigare beskrivits
(Dohlsten et al., WO 9201470), d.v.s. den skall framst vara
hydrofil och uppvisa en eller flera strukturer valda bland
amid, tioeter, eter, disulfid, etc. Finns osubstituerade obrut-
na kolvatekedjor skall de gärna vara korta, ex.vis med mindr
an 5 kolatomer i följd och helst sakna aromatiska ringar såsom
fenyl. De viktigaste bryggorna B är de som erhålles i rekombi-
nanta konjugat, d.v.s. då konjugeringen sker på genetisk nivå.
Har föredras oligopeptidbryggor vilka framst innehåller hydro-
fila aminosyrarester, såsom Gln, Ser, Gly, Glu och Arg.

Konjugatet enligt uppfinningen kan innehålla en eller flera
modifierade superantigen per biospecifik affinitetsmotpart och
vice versa. Detta innebar att T i formeln ovan forutom den
biospecifika affinitetsmotparten även kan innehålla en eller
flera modifierade superantigen. Analogt gäller för SA(m). I T
och SA(m) kan dessutom även finnas andra strukturer. Föredraget
är att antalet modifierade superantigen per affinitetsmotpart
är en eller två.

Syntes av uppfinningens nya konjugat kan utforas enligt i
huvudsak två olika principer: 1. Rekombinant och 2. Kemisk
sammankoppling av T och SA(m). Metoderna är för fackmannen
valkända och omfattar ett stort antal varianter. Det följer att
uppfinningen framst avser artificiella konjugat d.v.s. konjugat
som ej är naturligt förekommande.

Vid kemisk sammankoppling mellan ett modifierat superantigen
och affinitetsmotparten utnyttjas ofta funktionella grupper

(ex.vis primära aminogrunder eller karboxylgrupper), vilka finns på flera ställen i respektive förening. Detta innebär att den slutliga produkten kommer att innehålla en blandning konjugatmolekyler där ingående molekyler skiljer sig från varandra med avseende på den position vid vilken sammankoppling skett.

För rekombinant framställda konjugat (fusionsproteiner) gäller att framställd konjugatsubstans blir enhetlig med avseende på position för sammankoppling. Antingen kopplas aminoterminalen i det modifierade superantigenet till karboxyterminalen i affinitetsmotparten, eller vice versa. För Fab-fragment av antikroppar kan antingen lätta eller tunga kedjan användas i en sådan fusion. För närvarande är rekombinanta konjugat att föredra, med företräde för att aminoterminalen i det modifierade superantigenet är kopplad till den första konstanta domänen av den tunga antikroppskedjan.

Två olika metoder kan användas för att ta fram större mängder superantigen (inkluderande muterade och fuserade former) i *E. coli*: intracellulär framställning eller sekretion. Den senare metoden föredras här, framst av två skäl: (i) den medger att superantigenet får en nativ amino-terminal och (ii) korrekt veckat protein kan renas från periplasman och mediet. Intracellulär framställning innebär mer komplicerad rening och betyder vanligen att proteinet måste (åter)veckas in vitro (för att få en korrekt struktur). Detta utesluter inte att man kan framställa aktiva konjugat även i andra värdceller, ex.vis i eukaryota celler som jäst eller mammalieceller.

Framställning av muterade superantigen och selektion av mutanter med modifierad bindningsförmåga (affinitet) till MHC klass II antigen kan ske på kant sätt (ex.vis Kappler et al., *J. Exp. Med.* 175 (1992) 387-396). Se även vår experimentella del.

Ett konjugats förmåga att binda till T-cell receptorns V β -kedja och till målstrukturen samt att förorsaka lys av en målcell bestäms bland annat av peptiden (SA(m)) som är härledd från superantigen, biospecifik affinitetsmotpart (T) och bryggans längd (B) och struktur. Fackmannen kan optimera uppfinningens konjugat med avseende på bindningsförmåga och förmåga att ge lys genom att studera samband mellan effekt och struktur med hjälp av de modeller som utnyttjats i samband med tidigare

kända superantigen-antikroppskonjugat (se ovan angivna litteraturställen). Se även den experimentella delen nedan.

Med modifierad förmåga att binda till MHC klass II antigen avses främst att kvoten $IC_{50}(SA(wt)):IC_{50}(SA(m))$ är $< 0,9$ ($< 90\%$), såsom $< 0,5$ ($< 50\%$) och eventuellt även $< 0,01$ ($< 1\%$), alternativt att kvoten för affinitetskonstanterna ($K_d(SA(wt)):K_d(SA(m))$) uppfyller samma villkor (K_d mätt i nM). För bestämning av $IC_{50}(SA(wt))$, $IC_{50}(SA(m))$, $K_d(SA(wt))$ och $K_d(SA(m))$ se den experimentella delen.

Det är tidigare känt att vissa superantigen kan ha två eller flera säten som binder till MHC klass II antigen (Fraser et al., In: Superantigens: A pathogen's view on the immune system. Eds. Huber & Palmer, Current Communications in Cell Molecular Biology 7 (1993) 7-29). För denna typ superantigen gäller att bindningsförmågan skall vara modifierad hos minst ett av sätena, ex. vis som en reduktion av nyss nämnda dignitet. Eventuellt kan det räckas med att superantigenet modifierats så att skillnaden i affinitet för två säten som binder MHC klass II antigen ändrats, förslagsvis $> 10\%$ och företrädesvis genom reduktion av affiniteten i minst ett säte.

Det modifierade superantigenets (peptiden i icke-konjugat form) förmåga att binda till $V\beta$ -kedjan i T-cell receptorn bör generellt vara $> 0.01\%$ av motsvarande förmåga för det superantigen från vilket peptiden härstammar, dock gärna $> 0,1\%$ eller $> 1\%$ (mätt på motsvarande sätt som bindningsförmåga till MHC klass II antigen). När peptiden är konjugerad/fuserad till en biospecifik affinitetsmotpart som är riktad mot en ytstruktur på en cell och man onskar lysa cellen, är det väsentligt att bindningsförmågan (affiniteten) är sådan att konjugatet kan rikta och aktivera T-lymfocyter för lyses av cellen ifråga (SADCC enligt den experimentella delen med anpassning till det aktuella superantigenet). Detta i sin tur innebär som regel att nyss nämnda villkor för bindningsförmåga till $V\beta$ -kedja uppfylles. För föredragna $SA(m)$ är bindningsförmågan till TCR $V\beta$ ofta omkring 100% mätt som SADCC.

Main use of the conjugate s/fusion proteins of the invention.

The conjugates according to the invention are primarily intended for the treatment of the same diseases as the

conjugates between normal superantigens and antibodies. See the above-mentioned publications. Thus they may be administered either as the main therapy or as adjuvant therapy in connection with surgery or other drugs.

5 The pharmaceutical composition of the invention comprises formulations that as such are known within the field but now containing our novel conjugate. Thus the compositions may be in the form of a lyophilized particulate material, a sterile or aseptically produced solution, a tablet, an ampoule etc.

10 Vehicles such as water (preferably buffered to a physiologically pH value by for instance PBS) or other inert solid or liquid material may be present. In general terms the compositions are prepared by the conjugate being mixed with, dissolved in, bound to, or otherwise combined with one or more

15 water-soluble or water-insoluble aqueous or non-aqueous vehicles, if necessary together with suitable additives and adjuvants. It is imperative that the vehicles and conditions shall not adversely affect the activity of the conjugate. Water as such is comprised within the expression vehicles.

20 Normally the conjugates will be sold and administered in predispensed dosages, each one containing an effective amount of the conjugate that, based on the result now presented, is believed to be within the range of 10 µg - 50 mg. The exact dosage varies from case to case and depends on the patient's

25 weight and age, administration route, type of disease, antibody, superantigen, linkage (-B-) et.

The administration routes are those commonly known within the field, i.e. a target cell lysing effective amount or a therapeutically effective amount of a conjugate according to

30 the invention is contacted with the target cells. For the indications specified above this mostly means parenteral administration, such as injection or infusion (subcutaneously, intravenously, intra-arterial, intramuscularly) to a mammal, such as a human being. The conjugate may be administered

35 locally or systemically.

By "target cell lysing effective amount" is contemplated that the amount is effective in activating and directing T-lymphocytes to destroy the target cell.

Alternativ fi lds of us .

The inventive conjugates can also be employ d to quantitatively or qualitatively detect the structur against which the target-seeking group (T) is directed. In general
 5 these methods are well-known to people in the field. Thus, the modified superantigen may function as a marker group within immunoassays and immunohistochemistry meaning that the mark r group in turn is detected by for instance an antibody that is directed towards the peptide (SA(m)) and labelled with an
 10 enzyme, isotope, fluorophor or some other marker group known per se. Another method of analysis is to detect in a cell population cells that on their surface express a structure capable of binding to the target-seeking group (T). This use means that a sample from the cell population is incubated with
 15 T-lymphocytes together with the present inventive conjugat as in an SADCC assay. In case the incubation leads to cell lysis this is an indication that the population contains cells that on their surface express the structure.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185

EXPERIMENTAL PART

MANUFACTURE OF RECOMBINANT PROTEINS

Antibodies

5 The experimental work in connection with the invention has primarily been done with monoclonal antibody C215 as a model substance. This antibody is directed against an antigen in the GA-733 family (see for instance EP 376,746) and references cited therein and Larsson et al., Int. J. Canc. 32 (1988) 877-10 82). The C215 epitope has been judged not to be sufficiently specific for cancer treatment in humans. At the priority date mab C242 (Lindhölm et al., WO 9301303) was believed to be a better candidate, as judged from experiments with its fusion product with wild-type SEA.

15

Bacterial strains and plasmids

The E. coli strains UL635 (xyl-7, ara-14, T4^R, ΔompT) and HB101 (Boyer and Roulland-Dussoix, J. Mol. Biol. 41 (1969) 459-472) were used for the expression and cloning, respectively. 20 The vector pKP889 was used for expression of Fab-SEA fusion proteins (derived from the murine antibody C215) and the vectors pKP943 and pKP1055 for secretion of SEA (Fig 1). The Fab-SEA expression vector pKP889 is identical to pKP865 (Dohlsten et al. Proc. Natl. Acad. Sci. USA (1994) in press) 25 except that the spacer between C_H1 and SEA is GlyGlyAlaAlaHisTyrGly. Expression from pKP943 yields SEA with the native amino terminus. The use of pKP1055 results in SEA having a Gly residue added at the amino terminus. In both vectors the signals from staphylococcal protein A (Uhlén et al., J. Biol. Chem. 259 (1984) 1695-1702) are used for 30 transcription and translation and a synthetic signal peptide for secretion (L. Abrahmsén, unpublished).

In vitro mutagenesis

35 Mutations were made by polymerase chain reactions run on a Perkin Elmer Thermocycler. The reaction mixture (100 μl) contained: 1 x FCR buffer from Perkin Elmer-Cetus (10 mM Tris/HCl pH 8.3, 1.5 mM MgCl₂, 0.001 % (w/v) gelatine, an additional 2 mM MgCl₂, 0.4 mM dNTPs (Perkin Elmer Cetus), 2.5

units of Ampli Taq DNA polymerase (Perkin Elmer Cetus) and 100 ng DNA template. Primers were added to a final concentration of 0.8 μ M. The original template was a plasmid containing Staphylococcus aureus enterotoxin A gene identical to the one published by Betley et al. (J. Bacteriol. 170 (1988) 34-41), except that the first codon (encoding Ser) was changed to TCC to furnish a Bam HI site at the 5' end of the gene. Later a derivative containing more unique restriction enzyme sites introduced by silent mutations was used. Mutations introduced next to a restriction site were made with one set of primers, one of these spanning the mutation and the restriction site. For most mutations two set of primers had to be used and the PCR was performed in two consecutive steps. A new restriction enzyme site was introduced together with each mutation to enable facile identification. Oligonucleotides used as primers were synthesized on a Gene Assembler (Pharmacia Biotech, Sweden). To confirm each mutation the relevant portion of the nucleotide sequence was determined on an Applied Biosystems DNA-Sequencer using their Taq DyeDeoxy Termination Cycle Sequencing Kit.

Protein production and analysis

E. coli cells harboring the different gene constructs were grown overnight at room temperature (Fab-SEA vectors) and at 24-34°C (secretion vectors, the optimum depends on the mutation). The broth was 2 x YT (16 g/l Bacto trypton, 10 g/l Bacto yeast extract, 5 g/l NaCl) supplemented with kanamycin (50 mg/l). Fusion proteins were induced by addition of isopropyl- β -D-thiogalactoside to a final concentration of 100 μ M. (The protein A promotor used in the expression of non-fused SEA is constitutive). The cells were pelleted at 5000 x g and the periplasmic contents were released by gently thawing the previously frozen cell pellet in 10 mM Tris-HCl (pH 7.5) on ice during agitation for 1 hour. The periplasmic extracts were clarified by centrifugation at 9500 x g for 15 minutes. The Fab-SEA proteins were used without further purification. SEA and Gly-SEA were further purified by affinity chromatography on an anti-SEA antibody column. Polyclonal rabbit anti-SEA antibodies were previously collected from rabbits preimmunized

with SEA and purified by affinity chromatography on prot in G Sepharose[®] (Pharmacia Biotech).

Protein Analysis

The proteins were separated in precast polyacrylamide SDS Tris-Glycine Novex gels (gradient 4-20 % or homogenous 12 %, Novex novel experimental technology) and either stained with Coomassie Blue or used in Western blot. Polyclonal rabbit anti-SEA antibodies (above) were used to detect SEA in Western blot analysis, followed by porcine anti-rabbit Ig antibodies, and rabbit anti-horseradish peroxidase antibodies and peroxidase. With Fab-SEA fusion proteins peroxidase conjugated rat antibodies recognizing the kappa chain were also used (AAC 08P, Serotech LTD, England). 3,3'-diaminobenzidine (Sigma) was used for visualization of peroxidase.

Circular dichroism (CD) spectra were collected in a J-720 spectropolarimeter (JASCO, Japan) at room temperature (22-25°C) in 10 mM phosphate buffer, pH 8.2, with 0.02 mM ZnSO₄ and 0.005 % (v/v) Tween[®] 20. The scanning speed was 10 nm/min and each spectrum was averaged from five subsequent scans. The cell path length was 1 mm and the protein concentration 0.2 to 0.5 mg/ml. Guanidine hydrochloride (Gdn-HCl) denaturations at equilibrium were measured at 23°C by CD at 222 nm with a protein concentration of 0.3 mg/ml and a cell path length of 1 mm. These data were used to calculate the apparent fraction of unfolded protein (F_{app}). Equilibrium unfolding parameters were derived by fitting the data to a two-site folding process (Hurle et al., Biochemistry 29 (1990) 4410-4419).

BINDING AND FUNCTIONAL ASSAYS IN VITRO

Materials

Reagents: RPMI 1640 medium obtained from Gibco, Middlesex, England was used. The medium had a pH of 7.4 and contained 2 mM L-glutamine (Gibco, Middlesex, England), 0.01 M HEPES (Biological Industries, Israel), 1 mM NaHCO₃ (Biochrom KG, Germany), 0.1 mg/ml Gentamycin sulphate (Biological Industries, Israel), 1 mM Na-pyruvate (JRH Biosciences Industries, USA), 0.05 mM mercaptoethanol (Sigma Co., USA), 100 times concentrated non-essential amino acids (Flow Laboratories,

Scotland) and was supplemented with 10 % fetal bovine serum (Gibco, Middlessex, England). Recombinant SEA(wt), SEA(m) and the fusion products C215Fab-SEA(wt) and C215Fab-SEA(m) were obtained as described above. Human recombinant IL-2 was from Cetus Corp., USA. Mitomycin C was from Sigma Co., USA. $\text{Na}_2^{51}\text{CrO}_4$ was obtained from Merck, Germany. Phosphate buffered saline (PBS) without magnesium and calcium was received from Imperial, England.

Cells: The human colon carcinoma cell line Colo205 and the B cell lymphoma cell line Raji were obtained from American Type Cell Culture Collection (Rockville, MD) (expressing HLA-DR3/w10, -DP7, -DQw1/w2). The EBV-transformed lymphoblastoid B cell line BSM was a generous gift from Dr van De Griend, Dept of Immunology, Dr Daniel den Hoed Cancer Center, Leiden, the Netherlands. The cells were repeatedly tested for mycoplasma contamination with Gen-Probe Mycoplasma T.C. test, Gen-Probe Inc., San Diego.

SEA activated T cell lines were produced by activation of mononuclear cells from peripheral blood. The blood was received as buffy coats from blood donors at the University Hospital of Lund. The PBMCs were stimulated at a concentration of 2×10^6 cells/ml with mitomycin C treated SEA coated BSM cells (preincubated with 100 ng/ml SEA) in medium with 10 % FCS. The T cell lines were restimulated biweekly with 20 U/ml human recombinant IL-2 and weekly with mitomycin C treated SEA coated BSM cells. The cell lines were cultivated for 4-12 weeks before being used in the assay.

The viability of the effector cells, as determined by trypan blue exclusion, exceeded 50 %.

Determination of MHC class II binding characteristics of wild-type and mutant SEA

Radioiodination procedure. Appropriate amounts of wild-type or mutant SEA were radiolabeled with 10 to 25 mCi Na^{125}I using enzymebeads with the lactoperoxidase technique (NEN, Boston, MA). The reaction was stopped by quenching with sodium azide and protein-bound radioactivity was separated from free iodine by filtration through a PD-10 column (Pharmacia Biotech AB, Scllentuna, Sweden) with R10 medium as elution buffer.

Conditions were chosen to obtain a stoichiometric ratio between iodine-125 and protein of $\leq 2:1$. The radiochemical purity was verified by size-exclusion chromatography on a TSK SW 3000 HPLC column. The effect of the radioiodination on the binding activity was only tested for wild-type SEA and found not to be affected (data not shown).

Direct binding assay. Raji cells, $6 \times 10^4/100 \mu\text{l}$, previously cultivated in R10 medium, were added to conical polypropylene tubes and incubated ($22^\circ\text{C}/45 \text{ min}$) in triplicate with 100 $\mu\text{l}/\text{tube}$ of serially diluted ^{125}I -labeled wild-type or mutant SEA. The cells were washed with 2 ml 1% (w/v) bovine serum albumin (BSA) in 10 mM phosphate-buffered saline (PBS), pH 7.4, centrifugated at $300 \times g$ for 5 minutes and aspirated. This procedure was repeated twice. Finally, the cells were analyzed for cell-bound radioactivity in a gamma counter (Packard Instruments Co, Downers Grove, IL). The apparent dissociation constant, K_d , and the number of binding sites, N , at saturation were calculated according to Scatchard (Ann. N.Y. Acad. Sci. 51 (1949) 660-72) after subtraction of non-specific binding (i.e. binding after incubation with R10 medium alone).

Inhibition assay (inhibition of ^{125}I -labeled wild type SEA binding by mutant SEAs). These inhibition experiments were carried out as is described for the direct binding assay with slight modifications. Briefly, 50 μl of ^{125}I -labeled wild type SEA was allowed to compete with an excess of unlabeled wild type or mutant SEA (50 $\mu\text{l}/\text{tube}$) for binding to $6 \times 10^4/100 \mu\text{l}$ Raji cells. A tracer concentration yielding $\approx 40\%$ bound radioactivity in the direct assay was used to obtain maximal sensitivity in the inhibition assay. The displacement capacity of the competitor was expressed as the concentration yielding 50% inhibition (IC_{50}) of bound radioactivity. The binding affinity of the mutants relative to wild-type SEA was calculated using the equation:

$$\text{IC}_{50}(\text{SEA}(\text{wt})) : \text{IC}_{50}(\text{SEA}(\text{m}))$$

In order to analyze whether the mutants compete for binding to the same site on Raji cells as wild type SEA, the binding data obtained with SEA mutants were plotted as a log-logit function and tested for parallelism with the corresponding data for wild type SEA.

Inhibition assay (inhibition of the binding of fluor scent-labeled wild type SEA by unlabeled SEA and SEA mutants). Raji cells (2.5×10^5) were incubated with inhibitor (wild type or mutant SEA; 0-6000 nM) diluted in 50 μ l CO₂-independent medium (Gibco) supplemented with 10 % FCS, glutamine and gentamycin at 37°C for 30 minutes. Fluorescein conjugated SEA was added to a final concentration of 30 nM and the samples were incubated for an additional half hour at 37°C. The samples were washed three times with ice cold PBS supplemented with 1 % BSA (PBS-BSA) and finally kept in 0.4 ml PBS-BSA on ice until they were analyzed. From each sample 10 000 live cells were analyzed for green fluorescence on a FACStar® (Becton Dickinson) flow cytometer and the mean fluorescence value was calculated using the LYSIS II program.

15

SDCC and SADCC assays of SEA(wt), SEA(m) and their fusion proteins with C215Fab.

SDCC-assays. The cytotoxicity of SEA(wt), SEA(m) and their fusions with C215Fab against MHC class II⁺ Raji cells was analyzed in a standard 4 hour ⁵¹Cr³⁺-release assay, using in vitro stimulated SEA specific T cell lines as effector cells. Briefly, ⁵¹Cr labeled Raji cells were incubated at 2.5×10^3 cells per 0.2 ml medium (RPMI, 10 % FCS) in microtitre wells at defined effector to target cell ratio in the presence or absence (control) of the additives. Percent specific cytotoxicity was calculated as $100 \times ([\text{cpm experimental release} - \text{cpm background release}] / [\text{cpm total release} - \text{cpm background release}])$. The effector to target cell ratio was 30:1 for unfused SEAs and 40:1 for fusion proteins.

25

SADCC against of human colon cancer cells. The cytotoxicity of C215-FabSEA(wt), C215-FabSEA(m), SEA and SEA mutants against C215⁺ MHC class II⁻ colon carcinoma cells SW 620 was analyzed in a standard 4 hour ⁵¹Cr³⁺-release assay, using in vitro stimulated SEA specific T cell lines as effector cells. Briefly, ⁵¹Cr³⁺-labeled SW 620 cells were incubated at 2.5×10^3 cells per 0.2 ml medium (RPMI, 10 % FCS) in microtitre wells at effector to target cell ratio 30:1 in the presence or absence (control) of the additives. Percent specific cytotoxicity was calculated as for SDCC assays.

30

35

IN VIVO FUNCTIONAL EXPERIMENTS

Tumor cells. B16-F10 melanoma cells transfected with a cDNA encoding the human tumor associated antigen C215 (B16-C215) (Dohlsten et al., Monoclonal antibody-superantigen fusion proteins: Tumor specific agents for T cell based tumor therapy; Proc. Natl. Acad. Sci. USA, In press, 1994), were grown as adherent cells to subconfluency. The culture medium consisted of RPMI 1640 (GIBCO, Middlesex, UK) supplemented with 5×10^{-5} β -mercaptoethanol (Sigma, St Louis, MO), 2 mM L-glutamine (GIBCO), 0.01 M Hepes (Biological Industries, Israel) and 10 % fetal calf serum (GIBCO). The cells were detached by a brief incubation in 0.02 % EDTA and suspended in ice cold phosphate buffered saline with 1 % syngeneic mouse serum (vehicle) to 4×10^5 cells/ml.

Animals and animal treatment. All mice were 12-19 weeks old C57Bl/6 mice transgenic for a T cell receptor V β 3 chain (Dohlsten et al., Immunology 79 (1993) 520-527). One hundred thousand B16-C215 tumor cells were injected i.v. in the tail vein in 0.2 ml vehicle. On day 1, 2 and 3, the mice were given i.v. injections of 215Fab-SEA(wt) or C215Fab-SEA(D227A) in 0.2 ml vehicles at doses indicated in the figures 5a and 5b. Control mice were given vehicle according to the same schedule. On day 21 after tumor cell injection, the mice were killed by cervical dislocation, the lungs removed, fixed in Bouins solution and the number of lung metastases counted.

RESULTS

"Alanine scanning" of staphylococcal enterotoxin A.

Initially the structure of SEA was unknown and only speculations could be done about what side chains were surface accessible. Therefore, the majority of the mutants were chosen from alignments of homologous superantigens (Marrack and Kappler, Science 248 (1990) 705-711). Conserved (mainly polar) residues were chosen on the rationale that some of these superantigens are expected to bind to HLA-DR in a conserved fashion (Chitambar et al., J. Immunol. 147 (1991) 3876-3881). Alanine replacements were used according to published strategies (Cunningham and Wells, Science 244 (1988) 1081-

1085). During the course of this work the available information increased: i) it was shown that a Zn^{2+} ion is important for the interaction between SEA and MHC class II (HLA-DR) (Fraser et al., Proc. Natl. Acad. Sci. USA 89 (1991) 5507-5511), ii) a mutational analysis of staphylococcal enterotoxin B (SEB) was presented (Kappler et al., J. Exp. Med. 175 (1992) 387-396), and iii) the structure of SEB was presented (Swaminathan et al., Nature 359 (1992) 801-806).

Our first mutant showing a severely reduced affinity for HLA-DR, Asp227Ala, was found to co-ordinate the Zn^{2+} ion very poorly (data not shown). Assuming a common fold for SEA and SEB, the new data suggested two MHC class II binding regions: one involving the Zn^{2+} ion and one corresponding to the site defined in SEB. A second set of mutations were made on these assumptions. This second set of mutants were expressed in the form of SEA carrying a glycine added at the amino terminus. First the extension was shown to have no effects on the binding properties of wild type SEA (next section).

Most of the mutants were expressed and secreted by E. coli in a functional form as judged by analysis of the binding of monoclonal antibodies (Table I). Very low amounts were obtained of the mutants E154A/D156A and R160A. Consequently these were excluded from the study. The mutants having an Ala substitution in residues 128, 187, 225 or 227 were not recognized by the monoclonal antibody 1E. The latter two mutants showed a reduced level of expression (more pronounced at 34°C than at 24°C) and migrated faster during SDS PAGE, under denaturing but not reducing conditions (all other mutants migrated as wt SEA, not shown). As judged by CD spectra analysis the structure of D227A could differ slightly from native SEA (figure 2), but the stability was very close to wild-type SEA (measured as resistance towards Guanidine hydrochloride denaturation). The calculated ΔG between the mutant and native SEA was -0.16 kcal/mol and is only about 4 % of the ΔG° values (data not shown). Overall the signals in the CD analysis were low, as expected from a mostly β -sheet structure. It was recently reported that His 225 co-ordinates Zn^{2+} (unpublished data in Fraser et al (Proc. Natl. Acad. Sci. USA 89 (1991) 5507-5511). Since Asp 227 is involved in Zn^{2+} co-ordination (above) and

presumably located in the same β -sheet as His 225 this suggests that these two residues constitutes the zinc-binding nucleus found in zinc-co-ordinating proteins (Vallee and Auld, Biochemistry 29 (1990) 5647-5659).

Binding to MHC class II and T cell receptor

The MHC class II affinity was calculated from the amounts needed to compete with fluorescein-labeled wild-type SEA for Raji cell exposing large amounts of MHC class II. The displacement capacity of a mutant was calculated from the concentration yielding 50 % inhibition (IC_{50}) of bound fluorescence compared with the concentration needed with wild-type SEA as the competitor. For wild-type SEA and for some mutants, the result from this analysis was compared with the result from an analysis where ^{125}I labeled wild-type SEA was used as the tracer. As may be seen in Table II, the values obtained from these analyses correlates well

For six selected mutants the binding to MHC class II was measured directly using ^{125}I labeled mutant SEA (Table II). With the mutant His50Ala the values obtained from the two analyses correlated well but with the mutant Phe47Ala a large discrepancy was found: the direct binding indicated only 7 times weaker binding than wild type SEA but both competition analyses demonstrated around 70 times reduced binding. The data from two of the other mutants indicated two separate binding interactions. For the mutants H225A and D227A the affinity was below the detection limit also in this analysis.

We previously showed that fusion proteins composed of the Fab fragment of a carcinoma reactive antibody and SEA could be used to direct cytotoxic T cells to specifically lyse cancer cells, while the interaction between SEA and the T cell receptor (TCR) was too weak to be detected by itself (Dohlsten et al., Proc. Natl. Acad. Sci. USA, in press). Thus, in contrast to analyses involving the isolated superantigen the Fab fusion context enables a functional assay for the interaction between SEA and the TCR, independent of the MHC class II binding. Consequently, the efficiency of the different conjugates to direct T cells to lyse cells recognized by the Fab moiety was monitored in a chromium release assay. This

analysis confirmed that the mutations shown to affect the MHC class II binding did not affect the TCR binding (Table II).

Biological effects of the mutations

5 The proliferative effect was measured as the ability to stimulate peripheral lymphocytes to divide. All three mutants that compete very poorly for MHC class II induced little or no proliferation and the intermediate mutant His187Ala displayed some proliferative capacity, whereas the other investigated
10 mutants were indistinguishable from the wild type (table III). Harris et al (Infect. Immun. 61 (1993) 3175-3183) recently reported a similar severe reduction in T cell stimulatory activity for the SEA mutants F47G and L48G. Clearly a strong reduction in any of the two suggested binding regions results
15 in a severe effect on the ability to induce proliferation. This suggests that SEA cross-links two molecules of MHC class II leading to dimerization of the TCR and that this is needed to yield a signal transduction.

In contrast the efficiency of the different mutants in
20 directing in vitro stimulated SEA T cells to lyse MHC class II bearing target cells shows correlation with the binding affinity, rather than to the ability to compete (Table III). For example, the efficiency of F47A and D227A are only reduced 2.5 times and 300 times, respectively. Thus, here no inherent
25 requirement for divalency too is obvious. The increase in multivalency resulting from the significantly larger number of TCRs on the surface of activated T cells might partially shield the effect of a lower avidity in the SEA/MHC class II interaction. That dimerization is not needed to direct T cell
30 cytotoxicity has previously been demonstrated by the use of carcinoma specific bifunctional antibodies containing one anti-CD3 moiety and one anti-carcinoma moiety (Renner et al., Science 264 (1994) 833-35).

35 **In vivo functional experiments:** The results are represented in figures 6a and 6b. Treatment of mice with C215Fab-SEA(wt) and C215Fab-SEA(D227A) were both highly effective in reducing the number of lung metastases of B16-C215 melanoma cells. The therapeutic effect was essentially identical for the two

variants of the targeted superantigens. Treatment with C215Fab-SEA(wt) resulted in 70 % lethality at doses of 5 µg/injection. In contrast, no mice died when the same dose of C215Fab-SEA(D227A) were used. Taken together, SEA(D227A) is an example of a mutant with reduced toxicity and retained therapeutic efficiency when incorporated in a Fab-SEA fusion protein.

DISCUSSION

The structure of the complex between SEB and HLA-DR was recently reported (Jardetzky et al., Nature 368 (1994) 711-713). Most of the SEB residues identified to be involved in this interaction are conserved in SEA. Our data on mutant D227A indicates a weak affinity for the interaction between this site of SEA (the amino proximal site) and the MHC class II, having a K_d value higher than 8 µM. The K_d for the interaction between SEB and HLA-DR was recently reported to be 1.7 µM (Seth et al., Nature 369 (1994) 324-27). Here the different interactions between SEB, TCR and HLA-DR were investigated and it was shown that the complex between SEB and HLA-DR was not stably maintained in the absence of TCR. Plasmon resonance experiments indicated that this was because of a very fast off-rate. The avidity effects obtained if SEA cross-links two molecules of MHC class II followed by a subsequent dimerization of the TCR could explain how SEA may induce proliferative effects at concentrations well below the K_d . Assuming that the mutation F47A reduces the affinity of the amino proximal site below significance, the K_d of the Zn^{2+} site is around 95 nM. This hypothesis was recently strengthened by the observation that the mutants F47R, F47R/H50A and F47R/L48A/H50D show identical affinity for MHC class II at F47A (unpublished).

Based on the SEB structure (Kappler et al., J. Exp. Med. 175 (1992) 387-396) and on homology alignments (Marrack and Kappler, Science 248 (1990) 705-711), it is strongly suggested that His225 and Asp227 are located in the same β -sheet and thus the side chains could be proximal. Thus, most likely these two residues constitute the zinc-binding nucleus found in zinc-coordinating proteins (Vallee and Auld, Biochemistry 29 (1990) 5647-5659). Similarly to these mutants, the mutants with a replacement at residue 128 or 187 are also recognized by all

monoclonals except 1E. Fraser et al (Proc. Natl. Acad. Sci. USA 89 (1991) 5507-5511) showed that Zn^{2+} is bound to SEA and is needed for a high affinity interaction with MHC class II. The affinity for zinc was not affected by the addition of HLA-DR.

5 Based on this observation and the high affinity for Zn^{2+} (K_d of around 1 μM) a co-ordination exclusively provided by SEA and involving 4 fold co-ordination was suggested. Our data indicates an involvement of the four residues N128, H187, H225 and D227. The function of the former two residues is not yet
10 clear; instead of providing a ligand N128 could help in the deprotonation of D227. One argument for this is that the effect of replacing D227 is more severe than when replacing H225.

It was previously reported that there is a lack of correlation between the affinity of different superantigens for
15 the MHC class II and the capacity to stimulate T cells to proliferate (Chintagumpala et al., J. Immunol. 147 (1991) 3876-3881). These results might partly be explained by different affinities of the superantigens towards different TCR V β -chains. Here we have observed the same lack of correlation but
20 in contrast to separate superantigens the mutants display identical TCR affinity as shown in the Fab-SEA context. The most likely explanation for the lack of correlation is that two binding regions identified in this analysis represent two separate binding sites that yields not only a co-operative
25 binding, but which results in the cross-linking of two molecules of MHC class II, which in turn yields dimerization of two molecules of the T cell receptor. This would imply that the affinity of both sites are important to obtain the proliferative effect. A high avidity results from the
30 interactions within a hexameric complex involving two molecules of SEA, TCR and MHC class II. Thus the strong affinity/avidity of SEA towards MHC class II enables SEA interaction with the TCR despite a low direct affinity.

35 **Other biospecific affinity components:** A fusion protein of SEA(D227A) and an IgG-binding domain of staphylococcal protein A has been produced by recombinant technology and expressed in E. coli. This reagent has successfully been used to target T-lymphocytes to Mot 4 and CCRF-CEM cells (obtained from ATCC)

that are CD7 and CD38 positiv but HLA-DP, -DQ and -DR negative. The Mot 4 and CCRF-CEM c lls wer preincubated with anti-CD7 or anti-CD38 mouse monoclonals (Dianova, Hamburg, Germany). In order to enhance binding between the mous monoclonals and the IgG-binding part of the fusion protein rabbit anti-mouse Ig antibody was also added. In comparison with protein A-SEA(wt), protein A-SEA(D227A) had a deccreased ability to bind to Daudi cells expressing MHC class II antigen.

10 **Table I**

Confirmation of mutant structural integrity. The binding of six monoclonal antibodies was monitored.

Mutation	Monoclonal antibody ¹⁾					
	1A	2A	3A	1E	4E	EC-A1
15 Wild type	+	+	+	+	+	+
D11A/K14A	+	+	+	+	+	+
D45A	+	+	+	+	+	+
F47A	+	+	+	+	+	+
H50A	(+)	+	(+)	+	+	+
20 K55A	+	+	+	+	+	+
H114A	+	+	+	+	+	+
K123A/D132G	+	+	+	-	+	+
N128A	+	+	+	+	-	+
K147A/K148A	+	+	+	+	ND	ND
25 E154A/D156A	ND	ND	ND	+	ND	ND
R160A	ND	ND	ND	+	ND	ND
H187A	+	+	+	-	+	+
E191A/N195A	+	+	+	+	+	+
D197A	+	+	+	+	+	+
30 H225A	+	+	+	-	+	+
D227A	+	+	+	-	+	+

Footnotes: 1) A plus sign indicates binding, parenthesis indicate 50 to 90 % binding compared with wild type SEA. ND means not determined.

Tabl II

Binding of SEA mutants to the MHC class II and th T cell receptor. The latter was monitored as the ability to dir ct activated cytotoxic T-cells specifically to lyse carcinoma cells using Fab-SEA fusions of the different mutants (SADCC).

	Mutation	IC ₅₀ (nM)	IC ₅₀ (nM)	K _d (nM)	SADCC(% of wild-type) ¹
		SEA-FITC ¹	¹²⁵ I-SEA ¹	¹²⁵ I labeled ¹	
	wild type	50	38	13	100 ²
	Gly-SEA	50	ND	ND	100 ²
10	D11A/K14A	50	ND	ND	ND
	D45A	53	ND	ND	ND
	F47A	3150	2943	95	100
	H50A	150	132	32	100
	K55A	44	ND	ND	ND
15	H114A	48	ND	ND	ND
	K123A/D132G	188	75	12/237	100
	N128A	1150	ND	2.9/76	100
	K147A/K148A	58	ND	ND	ND
	H187A	1030	602	97	100
20	E191A/N195A	51	ND	ND	ND
	D197A	78	ND	ND	ND
	H225A	>9000	9600	ND	ND
	D227A	>9000	>10000	>8000	100

Footnotes: 1) ND means not determined. 2) In the Fab-SEA context the spacer between C_H1 and SEA ends with a Gly.

Table III

Biological effects of the mutations. The ability to stimulate resting T cells to proliferate and the ability to direct cytotoxic cells to lyse MHC class II exposing target cells were monitored (SDCC = Superantigen Dependent mediated Cellular Cytotoxicity).

	Mutation	Proliferation ¹	SDCC
		%	EC ₅₀ (relative) ¹
10	wild type	100	1
	Gly-SEA	ND	1
	D11A/K14A	ND	0.8
	D45A	50	1.3
	F47A	<0.2	2.5
15	H50A	20	1.4
	K55A	100	1.3
	H114A	ND	1
	K123A/D132G	40	2.1
	N128A	40	1.2
20	K147A/K148A	ND	0.7
	E154A/D156A	ND	ND
	R160A	ND	ND
	H187A	15	4
	E191A/N195A	100	1.1
25	D197A	ND	1.3
	H225A	<0.2	3x10 ²
	D227A	<0.01	3x10 ²

Footnotes: ND not determined.

LEGENDS TO THE FIGURES

General: The mutant SEA(D227A) (SEA mutant 9 (= SEA(m9))) was at the priority date the most promising SEA variant. Figures 3-6 therefore presents in vitro and in vivo results with this variant.

Figur 1.

Schematic outline of the plasmids used to express SEA and C215Fab-SEA. The coding regions and the two transcription terminators following the product genes are indicated by boxes. The gene encoding the kanamycin resistance protein is labeled

Km. lacI is the lac repressor gene. V_H and C_{H1} indicates the gene encoding the F₂ fragment of the heavy chain of the murine antibody C215. Likewise V_K and C_K indicates the gene encoding the kappa chain. Rop is the gene encoding the replication control protein from pBR322. The promoters directing transcription of product genes are shown as arrows, in pKP889 the trc promoter and in the other two vectors the promoter from staphylococcal protein A (spa). The region containing the origin of replication is indicated by ori. The only difference between SEA encoded by pKP943 and pKP1055 is a glycine residue added at the N-terminus of the latter. The SEA gene contained in the latter vector also contains more unique restriction enzyme sites, introduced by silent mutations.

Figure 2

Circular dichroism spectra for wild type SEA and for the mutants F47A and D227A, representing the most severely reduced mutations in each MHC class II binding region. The solid line is the curve for wild type SEA. The curves for the mutants are dotted or center, F47A respectively D227A.

Figure 3 shows the concentration dependency of superantigen dependent mediated cellular cytotoxicity (SDCC) for SEA(wt) and SEA(m9).

Figure 4 shows the concentration dependency of superantigen dependent cell mediated cytotoxicity (SDCC) for C215Fab-SEA(wt) and C215Fab-SEA(m9).

Figure 5 shows the concentration dependency of superantigen mAb dependent cell mediated cytotoxicity (SADCC) for C215Fab-SEA(wt) and C215Fab-SEA(m9) compared to free SEA(wt).

Figure 6a compares the therapeutic effects obtained in C57B1/6 mice carrying lung metastases of B16-C215 melanoma cells by treatment with C215Fab-SEA(wt) and C215Fab-SEA(m9).

Figure 6b shows toxicity of C215-SEA(wt) and C215-SEA(m9) for the treatments represented in figure 6a.

P A T E N T K R A V

1. Konjugat innehållande
 - a) en biospecific affinitetsmotpart (målsökande grupp) som binder till en förutbestämd struktur och
 - b) en peptid som
 - (i) innehåller en aminosyrasäkvens som är härledd från ett superantigen,
 - (ii) har förmåga att binda till en V β -kedja på en T-cell receptor, och
 - (iii) har en modifierad förmåga att binda till MHC klass II jämfört med det superantigen från vilket peptiden är härledd.

vilka delar är kovalent sammanbundna.
2. Konjugat enligt krav 1, kännetecknat av att
 - a) den biospecifika affinitetsmotparten är riktad mot en ytstruktur på en cell, och att
 - b) konjugatet har förmåga att aktivera T-lymfocyter för lys av celler som uppvisar strukturen på sin yta.
3. Konjugat enligt något av kraven 1-2, kännetecknat av att den biospecifika motparten är en antikropp eller ett antigenbindande fragment av en antikropp.
4. Konjugat enligt något av kraven 1-3, kännetecknat av att det är ett fusionsprotein.
5. Konjugat enligt något av kraven 1-4, kännetecknat av att peptiden är ett muterat superantigen.
6. Konjugat enligt något av kraven 1-5, kännetecknat av att peptiden är härledd från ett superantigen och att dess förmåga att binda till MHC klass II antigen är förändrad med minst 10 %.
7. Konjugat enligt något av kraven 1-6, kännetecknat av att superantigenet är stafylokockenterotoxin A, B, C₁, C₂, D eller E.

8. Konjugat enligt något av kraven 1-7, kännetecknat av att strukturen mot vilket den biospecifika affinitetsmotparten är riktad är en struktur som uttrycks på c llytan i förhöjd mängd vid sjukdom, exempelvis vid cancer, virusinfektion, autoimmun sjukdom eller parasitangrepp.
9. Satt att lysera celler från ett däggdjur, kännetecknat av att cellerna inkuberas med T-lymfocyter och ett konjugat enligt något av kraven 2-8, i vilket den biospecifika affinitetsmotparten är riktad mot en ytstruktur på cellerna som skall lyseras, under betingelser sådana att cellerna lyseras.
10. Satt att selektivt lysera celler (I) som förekommer tillsammans med andra celler (II) och som uppvisar en ytstruktur som framst förekommer på de celler (I) som skall lyseras, kännetecknat av att cellerna (I tillsammans med II) samtidigt kontaktas med ett konjugat enligt något av kraven 2-8, i vilket den biospecifika affinitetsmotparten är riktad mot en ytstruktur på cellerna (I) som skall lyseras, under betingelser sådana att cellerna (I) lyseras.
11. Satt enligt krav 10, kännetecknat av att cellerna (I) är associerade med sjukliga tillstånd såsom cancer, virusinfektion, parasitangrepp, autoimmuna sjukdomar etc.
12. Förfarande för att behandla ett sjukligt tillstånd hos däggdjur, vilket tillstånd innebar förekomst av specifika celler som är associerade med tillståndet genom att de uttrycker en sjukdomsspecifik ytstruktur, kännetecknat av att man till däggdjuret administrerar en terapeutiskt effektiv mängd av ett konjugat enligt något av kraven 2-8 i vilket konjugat den biospecifika affinitetsmotparten är riktad mot den sjukdomsspecifika ytstrukturen.

S A M M A N D R A G

Konjugat innehållande

- a) en biospecific affinit tsmotpart (målsökand grupp) som binder till en förutbestämd struktur och
 - 5 b) en peptid som
 - (i) innehåller en aminosyrasekvens som är härledd från ett superantigen,
 - (ii) har förmåga att binda till en V β -kedja på en T-cell receptor, och
 - 10 (iii) har en modifierad förmåga att binda till MHC klass II jämfört med det superantigen från vilket p pti-den är härledd.
- vilka delar är kovalent sammanbundna.







FIGURE 1

FIGURE 2






FIGURE 3




FIGURE 4




FIGURE 5

Therapeutic effect




FIGURE 6A

Toxicity




FIGURE 6B